Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

August 1, 2023

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 65 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being with us today as we go over Penumbra's earnings release for Q2 2023. You can find the press release and financial tables — including a reconciliation from GAAP to non-GAAP — under the Investors tab on our website, www.penumbrainc.com. On this conference call, we'll be making forward-looking statements under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. Because of certain risks and uncertainties — among them those cited in our 10-K for the year ended December 31, 2022, filed with the SEC — actual results might differ materially from what those forward-looking statements state or imply. So we urge you not to place undue reliance on them, and we encourage you to look at our periodic filings with the SEC, including that 10-K, for a fuller discussion of these factors and other risks that could affect our future results or the market price of our stock. Penumbra disclaims any duty to update or revise our forward-looking statements as a result of new information, future events, developments, or otherwise. Some financial measures on this call are presented on a non-GAAP basis. The corresponding GAAP measures and a reconciliation of GAAP to non-GAAP financial measures appear in our posted press release. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will then go over our financial results for the quarter, and Jason Mills, our Executive Vice President of Strategy, will talk about our 2023 guidance. With that, I'd like to hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thank you, Jee. Good afternoon, and thanks for being here on Penumbra's call covering the second quarter of 2023. Revenue across the company during Q2 came to $261.5 million, which represents growth of 25.5% versus the same period last year, both as reported and when measured on a constant currency basis. Within the United States, our top-line expansion sped up to 32% compared with a year earlier — the quickest pace we've seen in five years, if you set aside the second quarter of 2020, when COVID had an impact. The American uptick came from our thrombectomy offerings across both vascular and neuro, since combined U.S. thrombectomy sales climbed over 40% relative to last year. Domestic vascular thrombectomy revenue sped up to 50% growth year-over-year, while U.S. neurothrombectomy rose 20% compared with a year ago — the strongest expansion our American stroke business has posted in 5 years. Gross margins widened during Q2, in line with what we had anticipated, and we look for further improvement across the back half of 2023. Operating profitability also rose in the second quarter. Non-GAAP operating income reached $20.3 million, which works out to 7.8% of revenue for Q2; on top of that, our operating cash balance rose by $22 million on a sequential basis. Turning ahead, we anticipate delivering robust top-line growth, further gross margin gains, and rising profitability along with cash flow for the foreseeable future. Penumbra put up a highly successful quarter, and we remain at an early point in the journey toward bringing our proprietary thrombectomy technologies to patients across the United States and globally. The momentum we're seeing stems from the remarkable outcomes observed among patients treated with Lightning Flash, Lightning Bolt 7, and RED 72 with SENDit technology, given that each of these products is still in its early launch days. Beginning with Lightning Flash, we doubled the count of venous thrombectomy cases using Flash during Q2 relative to Q1, and our overall venous case volume rose by double digits sequentially, building on a very strong first quarter; we enjoyed yet another remarkable quarter with Lightning Flash, and plenty of additional new customers are only now hearing about Flash and beginning to try it over the coming quarters. Flash's transformative strength, speed, safety, and efficacy profile stands as the largest factor behind the product's outstanding early uptake. Another key element that physicians respond to is our transparent pricing, which follows the very same straightforward value-sharing approach we've stayed dedicated to throughout our company's history. Shifting to Lightning Bolt 7, U.S. arterial revenue climbed by double digits sequentially, marking the quickest expansion for this franchise since Lightning 7 debuted in early 2021. We observed Lightning Bolt 7 case volumes pick up during the final 2 months of the quarter as conversions away from surgery, lytics, and competing mechanical thrombectomy products gathered steam. Even so, we're at an even earlier point in the Lightning Bolt 7 launch than we were with Lightning Flash at this same time last quarter. That's because numerous prospective customers have chosen to let some time pass before kicking off the VAC process for Bolt, having already gone through that same process for Lightning Flash during the prior quarter. So because of that, we believe pickup for Lightning Bolt 7 is going to gain steam as this quarter progresses, on into Q4 of 2023, and then Q1 of 2024. When you put them side by side, Lightning Flash plus Lightning Bolt 7 have brought in a bigger number of pending hospital accounts than any prior launch we've ever done. Right now, we've got considerably more than 1,000 active submissions sitting with hospitals seeking approval for Lightning Flash or Lightning Bolt 7. To even be in submission for approval, some particular physician, or a group of them, has to step up as the champion for getting the product into those hospitals. What matters here is that most of those doctors are first-time customers for our thrombectomy offerings. And going beyond that, we anticipate quite a few more hospital submissions across the coming quarters. Looking back at how things have gone, whenever the submission process gets underway at a hospital, our track record of pushing products through those approval processes has been extraordinarily strong. With Lightning Flash and Lightning Bolt 7, we're only at the beginning. The way our commercial team carries out our strategy for Lightning Flash and Lightning Bolt 7 is amazing; we've got a well-defined plan for reaching most of the 800,000 venous and arterial patients treated annually in the United States across the next 5-plus years, and we're certain that computer-aided thrombectomy is where things are headed. Our neuro business likewise posted a solid quarter. I personally witnessed that momentum yesterday in San Diego at the Society of NeuroInterventional Surgery conference. Those remarkable early results with RED 72, which uses the inner catheter SENDit technology, point to an exciting stretch ahead for our stroke franchise; what we're hearing early on indicates SENDit might end up being the single most significant technology ever brought to market, tackling the toughest piece of stroke intervention: safe, fast, and repeatable trackability around the ophthalmic artery to the face of the clot. In our view, RED 72 with SENDit is the premium aspiration catheter, and its innovation sets it apart at the front end of a stroke intervention just as much as Thunderbolt might for clot removal once the catheter reaches the face of the clot. Over the past 2 quarters, we've observed favorable share shift tied to this technology, and we anticipate share shift in stroke that's even more meaningful in the quarters to come, which should deliver dominant share of the U.S. stroke market within the next 3 to 4 quarters. By launching RED 72 with SENDit, there's no need to hold out for Thunderbolt in order to achieve genuine share gain and market growth in stroke, and this technology only deepens our excitement and conviction regarding Thunderbolt when it gets cleared. On the international side, early wins are showing up as we roll out our first-generation computer-aided products in Europe, and we intend to broaden access to our most advanced thrombectomy products for our International vascular teams over the next few years. On top of that, our international teams and partners likewise perceive tremendous room to extend our leadership in stroke intervention beyond the U.S; through SENDit and Thunderbolt in the years ahead. Now, on the subject of immersive healthcare, I feel great enthusiasm regarding the further strides we made this quarter in our work alongside the Department of Veterans Affairs and our major private healthcare allies; together, we are reaching significant milestones as we track how well our VR platform performs clinically across a wide range of uses in physical rehabilitation as well as mental and cognitive health. Before handing things over to Maggie, let me state that we understand the bar for our business is set high; truthfully, the bar we set for ourselves is even higher. Our confidence is strong that we can achieve success in the near term even as we deal with unsettled and combative responses from competitors. We likewise hold the belief that the unavoidable should be sped along, which is why we are building the groundwork to serve every patient who stands to gain from our thrombectomy offerings. The guidance for our current year serves as a marker pointing toward near-term achievement, yet it represents only the opening year of a journey spanning more than five years ahead. We are devoting considerable focus to the markers of success across that lengthier horizon, and I believe our view of the bigger patient opportunity has never been as clear to us as it is right now, thanks to the input we are receiving on Lightning Flash, Lightning Bolt 7, and RED 72 SENDit. That clarity strengthens our growing conviction that we will keep producing robust revenue growth, expansion of gross margin, and meaningful profitability along with cash flow well into the foreseeable future. At this point I will pass the call to Maggie so she can walk through our financial results for the second quarter of 2023.

Maggie Yuen

executive
#3

Appreciate that, Adam. Greetings, all, and welcome to this afternoon's session. During this call, I'll walk through our Q2 2023 financial outcomes. The revenue and gross margin numbers I'll be covering reflect GAAP, while opex and operating income are reported on a non-GAAP basis. Our press release contains both the matching GAAP figures and the reconciliation bridging GAAP to non-GAAP financial measures. For the quarter that closed on June 30, 2023, we recorded total revenues of $261.5 million. Compared with the same period in 2022, that's an increase of 25.5% as reported and 25.5% on a constant currency basis. Looking at geography, the quarter's sales mix came to 71.4% U.S. and 28.6% International. U.S. Reported growth came in at 32%, and our International markets rose 11.7% as reported, or 11.6% in constant currency. The 8.3% sequential increase was primarily attributable to sustained momentum in U.S. vascular thrombectomy, plus gains in neuro thrombectomy across all regions. Moving on to revenue by franchise: in Q2 2023, our vascular business generated $152.7 million, which represents a 23.6% increase as reported and 23.7% in constant currency versus the prior-year period. U.S. thrombectomy growing 50% year-over-year drove that result, while the rest of our Global vascular business was approximately flat compared with a year earlier. For our neuro business, second-quarter 2023 revenue came to $108.8 million. That's a 28.3% increase as reported, or 28.1% in constant currency, compared with the same quarter last year. The growth came from new products across the U.S., Europe, and Asia Pacific. In the second quarter of 2023, gross margin stood at 63.8%. A year earlier, in the second quarter of 2022, it was 64.3%, and last quarter it was 62.6%. The improvement over the prior quarter was in line with what we expected, reflecting a richer thrombectomy mix and rising productivity from new product launches, which helped counter inflationary pressure. Because some start-up costs from the previous quarter were still weighing on gross margin in Q2, our operations group continues to perform strongly in meeting greater demand, and we anticipate additional gross margin improvement during the latter half of 2023. Turning to non-GAAP operating expenses, which leave out amortization of acquired intangible assets totaling $2.4 million, $1.8 million, and $2.4 million for this quarter, the equivalent quarter a year ago, and the prior quarter, respectively. Operating expense overall came to $146.6 million for the quarter, equal to 56.1% of revenue, versus $132.4 million, or 63.5% of revenue, in the same quarter last year, and $140.7 million, or 58.3% of revenue, in the previous quarter. Turning to the second quarter of 2023, R&D spending reached $21.5 million. For the same quarter in 2022, that figure stood at $19.6 million, while the preceding quarter came in at $20 million. SG&A costs during Q2 2023 totaled $125.1 million, representing 47.8% of revenue. A year earlier, in Q2 2022, those expenses were $112.8 million, or 54.2% of revenue, and in the prior quarter they amounted to $120.7 million, equal to 50% of revenue. Operating income for the second quarter of 2023 was $20.3 million, or 7.8% of revenue. During the comparable period last year, operating income was $1.6 million, and in the previous quarter it was $10.4 million, which worked out to 4.3% of revenue. We're still putting money into long-term growth and directing resources and investment wisely to back new product launches, and I'm really happy with how well our team has executed. I expect the trend of expanding operating margin to carry on through the second half of 2023 and past that. Let's move on to cash flow and the balance sheet. When the second quarter closed, we had $221.1 million in cash, cash equivalents, and marketable securities, with no debt — that's $22 million more than the previous quarter. This quarter-over-quarter rise in cash comes from better profitability and enhancements in working capital terms. At this point, I'll hand the call to Jason so he can go over our guidance.

Jason Mills

executive
#4

Thanks, Maggie, and good afternoon to all of you. Our 2023 revenue guidance is being raised to a range of $1.05 billion-$1.07 billion, reflecting 24%-26% growth compared with 2022 total revenue. For the full year 2023, we still anticipate that growth in our global vascular business will come in slightly above this range, while our global neuro business will grow below it. Looking at it quarter by quarter, we expect United States growth to pick up modestly from the record 32% we posted in the second quarter, whereas international growth should be mid-single digits in the third quarter because of seasonality and a tough year-over-year comparison, then re-accelerate to double-digit growth in the fourth quarter. All told, we anticipate global revenue growth of 23%-25% year over year in the third quarter, speeding up to 30%+ growth in the fourth quarter. Further down the income statement, we expect both gross margins and non-GAAP operating margins to continue expanding as we progress through the second half of 2023; we remain focused on achieving over 70% gross margins within a few years..; and over 10% operating margins by the end of 2023, with additional expansion anticipated in the years that follow. I'll now hand the call back to Adam for closing remarks.

Adam Elsesser

executive
#5

Thanks, Jason, Maggie, and Jee. I believe I'm expressing the sentiment of everyone at Penumbra when I say we've reached a pivotal point in this company's story. It's a point that's taken nearly 20 years to arrive at, and now we can plainly see how our work in computer-aided thrombectomy can serve virtually all patients suffering from clots in their arteries and veins. We're fully aware of the scale of effort still ahead; we've examined and drawn lessons from the finest organizations that came before us, the ones who tackled market development properly. Here's what I can commit to: I, along with the whole Penumbra team, the doctors we'll partner with, and the hospital systems, are prepared to meet this challenge; we'll persist until we achieve our highest ground. The coming five-plus years will demand hard work, yet they'll be the most thrilling stretch of Penumbra's journey. Thank you. Operator, let's begin taking questions now, for the next 40 minutes.

Bill Plovanic

analyst
#6

Thanks a lot, and good evening. That was a strong quarter. I'm honestly not sure where to begin. Let's take U.S. Neuro — could you walk us through it? From what I'm hearing, RED 72 with SENDit is catching even your own team off guard. So what exactly is driving that uptake, and then could you give an update on Thunderbolt? Should we expect that trial to be fully enrolled before the year is out? Is that still the plan, with a launch coming in 2024 after getting it out at year-end?

Adam Elsesser

executive
#7

Yes, those are terrific questions, Bill. Appreciate them. The good news is — I wouldn't describe RED 72 with SENDit as catching us off guard. Neuro has been our space for many, many years, so we understand it quite well. Still, it's clearly very encouraging for us. As you're aware, we've devoted the better part of 20 years to solving this problem — the challenge of steering appropriately sized catheters into the intracranial circulation, reaching M1 and further when the case calls for it. We've launched some excellent products. We've also hit some rough patches, as everyone knows, a few years back. Having a product today that tracks better than anything we've ever brought to market — better even than the old faded Xtra Flex — is genuinely thrilling for the team and encouraging, and honestly, physicians have really taken to it, since none of it matters if you can't reach the target. Thunderbolt is irrelevant if you can't get there. You need to reach the location as a matter of routine, and that's an essential element of the procedure. I'm glad Thunderbolt came up. Let me share a bit of an update. As I've said before, that timeline has slipped somewhat. Two factors are behind it. First — and we've talked about this — the initial roughly 100 patients took somewhat longer to enroll because of the mandated eight-hour window; enrollment has now picked up speed as the trial has moved along. That's a very encouraging signal. Second, the FDA requested that we change the safety endpoint from all serious adverse events at 24 hours to symptomatic ICH at 24 hours. That request and modification hasn't halted enrollment at all. It does bump the sample size up somewhat, by roughly 75 patients. Nothing about our trial or device prompted this request; instead, it appears aimed at aligning our trial with other stroke trials now underway, and from what we understand, those trials have likewise been delayed, possibly for the same reasons. We're working out the final details with the FDA, and once that's complete, we'll make a formal update, but it could add roughly another 12 months. Having said that, this gives us the chance to truly saturate the market with 72 through SENDit, and once again, we don't need to hold off on Thunderbolt for that to happen. We also have the ability to capture a meaningful share, but just as crucially, to expand the market with this premium offering. I believe the setup is there for a very strong stretch. Bill, you didn't pose this question, but I'm aware it'll be your initial follow-up, so if you don't mind, I'll take the freedom of addressing it right away. Specifically, this somewhat revised timing has zero effect on our forecasted figures for 2023, 2024, or 2025. I wanted to ensure I got ahead of that question.

Bill Plovanic

analyst
#8

Great, that's helpful. You've actually covered a portion of what I had in mind already. If we look at your 2023 guidance along with the increase, it seems to simply track the quarter with nothing extra added. What I'd like to understand is how we ought to frame — you know — what assumptions sit behind both the bottom and the top of that range, given how significantly you outperformed during the quarter? From what our numbers suggest, anyway, it appears you aren't factoring in much for the back half of the year. I appreciate you fielding my questions.

Jason Mills

executive
#9

Yes, Bill, thanks for asking. That's a solid one. To start, I want to point out that across the two calls we've held this year, we've lifted our revenue guidance by roughly $60 million. My sense is that figure comes to around three times the cumulative amount by which our results beat consensus across those same two quarters. Looking ahead, there are a few points worth flagging. I want to cover what the guidance we've just updated takes into account and expects, and also perhaps what it leaves out or doesn't entirely reflect. To begin with, we anticipate the U.S. portion of our business will expand at a quicker pace during the back half of the year than it did in the front half. We did touch on that point in our prepared remarks. A big part of that comes from Flash, Bolt, and SENDit, clearly, and it also shows what we expect: that peripheral thrombectomy growth, in both the U.S. and around the world, will pick up speed during the back half of the year. One more thing I'd mention: we're enthusiastic about the hospital submission activity we're seeing, with a record number of mostly new accounts in the pipeline. Naturally, the schedule for these processes varies — it might run from a couple of months to nine months or longer. At this point, I'd say we've taken a sensible approach in how we're building this into our guidance. Looking at the rest of this year and heading into the following one, I'd say there's plenty ahead for us to feel positive about.

Bill Plovanic

analyst
#10

Thanks for taking my questions.

Adam Elsesser

executive
#11

Thanks, Bill.

Robbie Marcus

analyst
#12

Thanks, and good to get a chance to ask. Let's begin with peripheral vascular — U.S. sales apparently rose 50%, while the remaining portion of that business didn't move. Could you talk us through the trend there? Is there some kind of pressure or deceleration in coils, or anything overseas we should know about? The vascular segment came in a bit under what the street expected. I'm just trying to get clarity — U.S. growth sounds excellent, but what about the other parts of vascular?

Jason Mills

executive
#13

Appreciate that, Robbie. On the whole, we view the quarter as quite strong for vascular. Clearly, the U.S. — as you noted, the U.S. We saw a 50% increase in our peripheral thrombectomy segment. Within the United States, our overall thrombectomy operation for stroke grew by more than 40%. When we look outside the U.S., both the coil and thrombectomy areas are still at a relatively early stage; Lightning 12 and Lightning 7 have only recently launched in those markets, so considerable effort remains ahead. I wouldn't characterize anything as problematic—it's simply that not all of our top-tier offerings are available abroad yet; meanwhile, in the U.S., those products are the key thing expected to fuel expansion. Our guidance, I believe, captures what we anticipate from the vascular division: very robust and quickening growth, with the American market serving as the primary engine behind it.

Adam Elsesser

executive
#14

And honestly, that's what we see as the opening, since we're taking these offerings — especially Flash, plus Lightning Bolt 7, RED 72 with SENDit, and Thunderbolt — into those regions, because that gives us a chance to keep up comparable expansion in the International markets. What's really behind it is innovation and technology, which have always been what sets us apart.

Robbie Marcus

analyst
#15

Perhaps we could just touch on the sequencing a bit. You provided a figure, and I think it was 23%-25% growth for the third quarter — please correct me if that's not right — and then greater than 30% for the fourth quarter. So that comes in below what the street has for Q3 and above what they have for Q4. Could you walk us through the puts and takes there, plus how confident you are in that greater than 30% figure for the fourth quarter? Thanks a lot.

Jason Mills

executive
#16

Yeah, appreciate the question, Robbie. We did highlight that. As you're aware, quarterly guidance isn't something we normally give, but we felt it mattered to call out the third quarter. The consensus view of how the third quarter had been modeled, I think, didn't fully capture the momentum in the United States, and the International markets were simply a touch too high. That's the put and the take for the third quarter. Where we anticipate getting the growth — not only in the coming quarter, but for some time — is, I think, the United States market. That's where people, I believe, are looking to see our growth, since that's the only place Flash and Bolt are available right now. When it comes to the fourth quarter, the year-over-year comps internationally simply aren't the same as what they are in the third. As we said, we expect double-digit growth. And again, that's combined with a U.S. business that will, obviously, still carry a lot of momentum, as we've noted, coming off the second and third quarters.

Robbie Marcus

analyst
#17

Great. Thanks for taking the questions.

Adam Elsesser

executive
#18

Thanks, Robbie.

Larry Biegelsen

analyst
#19

Afternoon, and thanks for fielding this. Nice quarter — congrats. Adam, before anything else, a couple of quick clarifications. On that Thunderbolt 12-month delay, what drove it? Was it a filing matter — previously you'd said filing would happen by the close of 2023, so has that now shifted to the close of 2024?

Adam Elsesser

executive
#20

Right, we'll lay out all the details and the schedule for that once I've wrapped up with the... Broadly speaking, I wanted to put a number on it as roughly a 12-month extension. What matters most — and I truly want to emphasize this — is that performance isn't something we're waiting on, and our second consecutive quarter's figures show it: our neuro business isn't sitting around for Thunderbolt. We've got this incredible premium offering that keeps winning share. Everyone at SNIS, where we just were, was talking about it; we're in genuinely strong shape. Beyond that, once Thunderbolt arrives, we'll be able to address the other half of the procedure — not merely reaching the site, but guaranteeing that in each case we can extract the clot. I want this to be completely unambiguous for everyone, and Larry, I appreciate the question — the position we're in, being able to pursue both halves of this procedure at this point, is essential. I believe it's widely understood how much trackability matters. It was something discussed around us for a good while at our stroke gatherings. Having a product that performs this remarkably and gains this much share — which is why I said I think we'll capture the dominant share — is terrific. And then layering Thunderbolt on top, and watching how it sustains the growth trajectory of our stroke business, is a wonderful indicator. Thanks for asking.

Larry Biegelsen

analyst
#21

Yes. Adam, I wanted to build on what Robbie asked. Embolization has performed well for your company, expanding at a minimum of mid-teens, as you know. How did it perform in this quarter? I'm curious whether the sales team might be somewhat pulled in different directions by bringing two products to market. Let me also slip in something about vascular. It appears difficult to see how vascular could outpace neuro for the entire year, since during the first six months neuro expanded far more quickly than vascular. I appreciate you answering these.

Adam Elsesser

executive
#22

Yes. Those are truly excellent follow-ups. Regarding the coils first, we already hold a majority of the market with coils, so naturally that will decelerate relative to the start of the two biggest product introductions in our company's history. The figures make that fairly clear. Make no mistake, all of us take pride in our coils. They perform excellently and deliver meaningful clinical value. It's simply inevitable given the circumstances. On the vascular matter, I believe we addressed that during the script. The number of hospitals adopting Lightning Flash and Lightning Bolt is far greater than what we currently have. We remain nearer to the start. I stated something quite precise: we have considerably more than 1,000 submissions within the U.S. by itself for Flash and Bolt. We are far—these are largely first-time customers, and that process, as it unfolds, will clearly propel things. These are people who witnessed it, tried it a single time, and are now navigating the submission process at their own hospitals. The magnitude here differs from anything else we have ever introduced in our company's history. I simply wanted that to be clear; it means it may not occur overnight, yet it is, it is occurring. I must credit—it reflects the sales organization putting in the effort to, to make that happen, and equally the remarkable innovation that is attracting that many new customers to want this product. Once you calculate that, the vascular growth matter resolves on its own.

Jason Mills

executive
#23

Sure, Larry, the one additional point I'd make is purely on the figures side — worldwide vascular accounted for roughly 58% of overall revenue for us. During the third quarter that share will rise somewhat, maybe just under 60%, and then in the fourth quarter vascular will probably represent more than 60% of what we do globally.

Larry Biegelsen

analyst
#24

Thanks, Jason.

Margaret Kaczor

analyst
#25

Hi there, good afternoon, all. Appreciate you taking our questions. There were really two areas I hoped to dig into further. First, I'd like to get a handle on the magnitude — I suppose — of those 1,000 active hospital submissions seeking approval for Flash and Bolt. I don't know whether you'd be open to sharing, say, how many hospitals you currently sit at, relative to your target hospitals and that figure of 1,000+, as we look ahead against the potential accounts, correct? Then, a comparable question regarding the adoption curve for those who may have trialed Flash and Bolt. Could you give us a sense of their scale, roughly? Is it month one, try a few cases, sort of set it aside, bring it on, or does an inflection arrive fairly quickly as we move through the year? That would help us gauge growth.

Adam Elsesser

executive
#26

Yes, those are truly excellent questions. Allow me to try my best to address that. What does well over 1,000 submissions signify — the finest way I can describe it is this: we sit nearer the start of this launch than its finish, all right? That is the proper manner of framing it. There remains more ahead of us than what has already been achieved. It really accelerates — you know, apart from perhaps one or two cases, a product essentially cannot be used unless it is formally brought on via this process. That's the gating item. Plenty remains for us to do to get that moving. Once someone does bring it on, our experience thus far has been that this is fairly sticky business. I believe that's partly what pushes new customers we've never had before to be so intrigued. Word of mouth, physicians conversing with physicians, exchanging their experiences — that has proven very sticky. You, you tend to find a lot of, you know, plenty of physicians who want this to happen as quickly as possible so they can begin using this. That explains why you hear the confidence we hold regarding, you know, not merely the remainder of this year, but, you know, moving into the, the, the prior, the future years too. We simply have not, have not had an experience like this, where, where the technology itself is fueling a, a scale of adoption or interest, as we have witnessed.

Margaret Kaczor

analyst
#27

All right. So, you mentioned that growth above 30% that you expect once we reach Q4. Obviously, the comparisons for this year aren't as tough as what's coming in 2024. How are we supposed to interpret that? The street has it at mid-teens. Everything you're telling us sounds really upbeat, whether it's vascular or even neuro. It comes across as a fairly sharp slowdown, and that doesn't match what your commentary implies. Perhaps you could reconcile those two things — the remarks and the figures. Thanks.

Adam Elsesser

executive
#28

Yes, well, we're still in summer, so I'm hoping you'll forgive me for declining to provide 2024 guidance while we're midway through summer 2023. What we're saying, and what we're telling you about what lies ahead of us, should be taken as the strongest indicator of how confident we feel. Putting a specific percentage on that right now would be difficult and too early, yet that doesn't mean I'm any less excited about each of those three products we're in the process of launching.

Margaret Kaczor

analyst
#29

Alright, thank you. It was worth a shot.

Adam Elsesser

executive
#30

I like that you gave it a try.

Analyst

analyst
#31

Hello there, good afternoon; Anthony here, filling in for Joanne. Appreciate you taking our questions. During the prior quarter, I believe you mentioned supply might be a headwind or a gating factor for the Flash update. I'm just wondering whether that was again the situation this quarter, and then as a quick second question, could you discuss the adoption trends you're observing with Flash in PE cases compared to DVT? Thank you.

Adam Elsesser

executive
#32

Yes, excellent question. Thank you. You know, we, we didn't actually need to concentrate much on supply. I mean, don't misunderstand me, the operations team is putting in incredibly hard work to make sure we don't run into that issue. I very specifically, at the start of the quarter, stated we didn't anticipate that would, would constrain us, the real. Our hope is to stay ahead of that curve, moving forward, and the team is working diligently. When it comes to PE versus DVT, we aren't truly seeing any difference. You know, there are, obviously, you know, competitive reactions and physicians who are going to hold different viewpoints initially. What we're observing is both of those areas, whether it's a PE case or a DVT case, are incredibly successful, and physicians are responding to that. Some might begin with one and then move to the other and vice versa. There isn't a trend that I would yet identify showing that one is better or different than the other at this point. I don't expect that to be the case, given the sheer volume of cases and the success we're seeing.

Analyst

analyst
#33

Great. Thank you.

Adam Elsesser

executive
#34

Thank you.

Matthew O'Brien

analyst
#35

Thanks for taking my question. Let me try to draw this out a bit — the acceleration in the back half. The stock is down roughly 5% after the market closed, and I'm certain part of that relates to Thunderbolt, though I'd guess the bigger factor is the vascular business, despite the U.S. performing really well. That's because we're facing a larger ramp in the second half, and Jason, you're quite familiar with those sizable second-half ramps and the worries that come with them. When it comes to achieving the acceleration in Q3 and Q4, what are you assuming for the vascular business regarding those active submissions and turning them into users or getting existing hospitals to increase their utilization?

Jason Mills

executive
#36

Yeah, Matthew O'Brien, I'll handle the first part of that, and then Adam can follow up and tidy things after me. The growth for the third quarter sits in a fairly strong range. For Q3, the guidance clearly has a top end of 25%, against a pretty robust third quarter from last year. Our view is the United States will fuel that. I mean, it's difficult to speed up beyond the growth we delivered in the U.S. during the second quarter. We believe we can at minimum match that growth and perhaps demonstrate a bit of acceleration in Q3. You also raised the submission process, and we've said something about it — I'll let Adam address it more fully. When I say we've been appropriate about what we've baked in, I think you could interpret that as us being suitable in our assumptions. We aren't including factors where we lack control over timing or other elements, even though once the submission process gets underway, our track record shows we succeed at a high rate in getting through it favorably.

Adam Elsesser

executive
#37

Right, I don't really — I believe you handled that quite nicely. There isn't anything particular for me to add, other than, you know, we have consistently approached our guidance by keeping it quite realistic and ensuring that we provide the full picture regarding this; that's the reason we're giving you the count of submissions in hospitals for Flash and, and both in a few of the remarks concerning SENDit, since that too is going to be a fairly major piece of our neuro growth for, for a good while.

Jason Mills

executive
#38

To wrap things up, let me build on what was just said. As you're likely aware, Matt, overseas business in Q3 or Q4 typically shows some seasonality, with Q4 coming in as the peak period. Our guidance captures that pattern. In fact, we included our international growth projections for Q3 as well as Q4. That mirrors the usual seasonal patterns along with our knowledge of the international business, paired with what we anticipate in the U.S. from those three products we've discussed at length during this call.

Matthew O'Brien

analyst
#39

Understood. Thanks for that response. Just one more brief item. Everyone keeps discussing what lies ahead regarding all those additional active sites currently evaluating the fresh offerings, yet how about the ones that have already taken up and cleared the VAC? What patterns are you observing when it comes to utilization, and more particularly, reorder rates? Are you witnessing reorder rates of 90s plus coming from those accounts?

Adam Elsesser

executive
#40

Yes, that is an excellent inquiry. Allow me to attempt to address it. What I can say is that this product's reorder rates are clearly exceptionally robust. Absent that, you would not be seeing all these brand-new customers who previously had zero interest in ever utilizing our thrombectomy offerings. The enthusiasm of those currently using it and spreading the word is what fuels this. Those two things are connected. There remains capacity, and I believe all of you are aware of this, having observed it and spent many years in this space. You encounter numerous physicians, and within our specific domain, there are several, you know, physician subspecialties, as many as 3 distinct ones at each hospital. Once a hospital receives the product, that does not guarantee — although sometimes it does, just not always — that each and every physician across all 3 subgroups begins using it. Beyond the new locations arriving, there is still substantial potential during the coming stretch to generate greater usage inside hospitals that have already received approval.

Matthew O'Brien

analyst
#41

Got it. Thanks.

Adam Elsesser

executive
#42

Thank you.

Jason Mills

executive
#43

Thanks, Matt.

Pito Chickering

analyst
#44

Hi there, good afternoon, and congratulations on a solid quarter. You gave us a figure for how much the U.S. vascular business expanded, saying it was up 50% compared with the same period last year. Of that, how much came from growth over the first quarter? You also told us U.S. growth would speed up mostly during the third quarter. So looking at it quarter to quarter, what sort of expansion should we expect for the U.S. vascular market as we move from the second quarter into the third?

Jason Mills

executive
#45

Right, we didn't put a number on that quarter-over-quarter increase. What we did say — and actually we did provide this — was that U.S. venous overall posted a strong double-digit rise sequentially, while U.S. arterial was also up double digits. Together those account for the large majority of it. Coronary also delivered a solid quarter for us. Growth there was a bit slower, yet it still reached double digits compared with the prior year.

Pito Chickering

analyst
#46

All right, excellent. Now regarding margins, EBIT margins improved quite well during this quarter alongside that robust revenue growth. Could you give us any refreshed guidance on how we ought to think about the exit rate for Q4 of this year?

Jason Mills

executive
#47

Sure, I'll take that first, and then perhaps addressing the second half of what you asked, as I mentioned during my prepared remarks, we do anticipate being above 10% on an operating basis — pro forma operating margins, that is — when we close out 2023. What's key, I believe, is that we don't view that as the point where it levels off. We anticipate further expansion after that throughout 2024 and going forward. Maggie, anything you'd like to add?

Maggie Yuen

executive
#48

That's right, I believe you've captured it nicely. With the favorable mix persisting alongside leverage from volume and our ongoing scaling, that's the pattern we expect to keep observing across the year.

Pito Chickering

analyst
#49

Great. Thanks so much.

Shagun Singh

analyst
#50

Great. Thank you so much. I wanted to pose the 2024 question, maybe from a different angle. I'm simply attempting to determine how the second year compares with the first. You know, you've described this as a launch spanning multiple years. You know, you've mentioned a runway of at least five years. When we consider year two, and, and it also appears there's a process involved in getting the product on board. When you think about year two, do you anticipate, you know, growth will be stronger, similar, you know, or lower than 2023? Just, just anything that could help us better assess the opportunity would be useful.

Adam Elsesser

executive
#51

To start, I appreciate you asking, and just as much, I'm grateful you let me know ahead of time that this was coming and that you'd attempt to put it differently. My response stays the same: we're still in the summer of 2023. So clearly, we won't get into those kinds of details. When I look at what we discussed this quarter regarding the road in front of us, my goal isn't really to draw a line between the past and the future. Instead, I want to convey just how much enthusiasm we're seeing reach far into our subspecialty areas — at a scale and in a manner unlike anything we've experienced with any launch in our history. That's genuinely thrilling, since it tells us these offerings are performing and delivering real results. Take a vascular surgeon, for instance—someone who's spent years performing open procedures on the arterial side and never had any interest in hearing about what our earlier generations had to offer. Now they get a look at Bolt, feel curious enough to try a single case, and then come back and tell us they plan to switch everything over. That doesn't really happen. It isn't typical, and it tells us there's still a great deal of ground to cover, which makes this a thrilling time for us. As for putting numbers on it across 2023, 2024, 2025, and beyond? It comes down to this: plenty of effort still lies in front of us. There's work ahead of us. We need to be inside the hospitals. We need to confirm that we've got that in place. Every bit of that is encouraging, and it leaves us positioned very well. I'm sorry that I can't yet put a number on it for 2024. Naturally, when the right moment comes, we will. We're sitting in a genuinely strong position, and that has us quite enthusiastic. We recognize the effort still required, but these launches — each of the three — aren't like anything we've had previously.

Shagun Singh

analyst
#52

Understood. Next, I have one about margins. I'm curious about your plan for moving past the +10% mark, perhaps reaching +20%. Could you walk us through how you see margin expansion unfolding, both for this year and for years ahead? Should we expect a more linear path, or is there another way we ought to view it? Any general sense of direction would help. Thanks for taking my question.

Maggie Yuen

executive
#53

Yes. Thanks for asking. On margin, as Jason mentioned in his part, we reaffirm and keep aiming at a 70% growth margin within a few years. From 2023 to 2024 and afterward, we're moving at a fairly solid pace and should, in directional terms, keep seeing that same expansion; that also carries over into how operating margin trends, since we keep scaling quite well and have the infrastructure in place so we can scale and deploy resources efficiently. Given the margin expansion trend we've observed up to now, we can keep expecting that as we move into the next year.

Shagun Singh

analyst
#54

Thank you.

Adam Elsesser

executive
#55

Thank you.

Jason Mills

executive
#56

Thanks a lot.

Analyst

analyst
#57

Hello there, is my audio coming through fine? This is Ryan here, using Sam's connection. Since I'm over at SNIS, I dialed in through his line.

Adam Elsesser

executive
#58

You're coming through clearly. Yes, we've got you.

Analyst

analyst
#59

Oh, wonderful. That's great. Hello, everyone. There are two things I'd like to ask. I've been sitting here taking in every one of the clinical sessions, and it's obvious that you're going head-to-head with Thunderbolt for patients in these trials. Adam, I'd like to get a sense of where you stand on cyclic aspiration as it is today compared with where it stood perhaps 12 months back, or when you were first starting down this path. Has your thinking shifted, or in what ways has it stayed the same regarding the market opportunity for cyclic aspiration versus options such as large bore aspiration, and what do you believe that opportunity can deliver once Thunderbolt ultimately reaches the market?

Adam Elsesser

executive
#60

Yeah. That's a terrific question, and it's a fitting one, since you happen to be right in the middle of SNIS at this moment. Let me just. A few terms so that we're all on the same page, and then, I truly, truly want to, because this seems to be the third or fourth time that, that this question has come up, and I'm not certain why what I'm telling people isn't sinking in. Cyclic aspiration is a different thing. Cyclic aspiration isn't what we do. That's simply switching a pump on and off. It, it accomplishes nothing. There's no genuine benefit from it. Modulated aspiration is a completely separate matter, that's the mechanism behind Thunderbolt; it's likewise the mechanism behind Lightning Bolt. Clearly, we've now treated, you know, something like 1,000 patients using Lightning Bolt, and it's, as I said a moment ago, it's remarkable; it's incredible technology that is shifting how people think about treating patients after years of doing something else. So there should be no confusion whatsoever regarding how enthusiastic and excited I am about modulated aspiration for removing clot from the body. I want that to be completely clear; now, there's the matter of now, as neuro of, you know, Thunderbolt, you know, large bore aspiration. Large bore aspiration catheters have existed for some time. Not one of them, based on my understanding, is actually clear. They're either participating in a trial or they carry a guide catheter indication or they're being used off label since they're in a trial. A number of those trials are underway. Those tend to be guide catheter sizes where the aim is to push them up to the M1. You can ask around about whether that's, you know, the current fad or not. I believe the answer is pretty obvious. Let's concentrate on the most important element of starting a stroke case. You've got to get there. You've got to get there. We now possess a technology that delivers an appropriate size catheter up to the clot more quickly and more easily than any other product we've ever had or that anyone else has ever had. That ought to be something we're excited about. Beyond that, Thunderbolt has us really enthusiastic too, along with what it’s producing, and we’re eager for its release since we already understand—from the trial and clearly from how heavily Lightning Bolt gets used—how it performs. That’s a process requiring time. It doesn’t occur right away, as you know. Thunderbolt will need somewhat more time, yet during that stretch, there’s no need to hold off on what we’re already doing, which is capturing a meaningful share and probably expanding the market simultaneously. I happened to be there just yesterday—sorry I didn’t get to see you—but excitement is higher than it has ever been. It’s returned. Enthusiasm at levels from before the pandemic. We met with physicians discussing going out into the community and performing the work needed to push this forward; much of it centers on the notion that access—reaching the clot using a suitably sized catheter such as RED 72 with SENDit—is the solution. I’d like to. There’s a serious misconception if anybody believes that what I’m stating regarding Thunderbolt is unfavorable. Thunderbolt is excellent; it’s also good to have something just as excellent that accomplishes a different task, namely RED 72 with SENDit.

Analyst

analyst
#61

Understood completely, Adam. I appreciate you clarifying that. So, my final question. You brought up pricing and the advantage you're seeing during that quarter for Lightning, or, as you mentioned, the advantage you're seeing on SENDit with RED 72. Could you share any insight regarding how that pricing advantage compares with, let's say, a volume mix that's factored into your guidance, since you're receiving some price premium for these technologies when we consider the outlook for the rest of the year?

Adam Elsesser

executive
#62

Yes. That is a truly excellent question, and I'm happy you raised it. I brought up pricing for a somewhat different purpose. We simply operate with an easy structure. There's one price, it's straightforward, everybody is aware of it, and we're told that this is a valuable approach to doing business. Even so, our pricing has always been fair, that's the reputation we've earned, and that reputation remains. I believe that matters since, when you've been operating for many years, your reputation, the way you carry yourself, and the fairness of what you charge all count. That said, clearly there's a modest premium for our products; we discussed this regarding the new products. It's somewhat reduced because, as with Flash, no separator is required. Therefore, most of our guidance and the success across the past couple of quarters comes from greater usage of the products, not from price alone. The reason it's worth stating is, first, it's accurate, but even more significantly, it can be sustained. Price has a brief useful life, and it isn't something we've ever—we'll accept a suitable price when needed, but we aim to expand our business through lasting share gain and market growth, which differs greatly from a temporary, one-year lift from price.

Analyst

analyst
#63

Thanks. Thanks, Adam.

Adam Elsesser

executive
#64

Thank you.

David Rescott

analyst
#65

Oh, excellent. Thank you for allowing me to ask some questions, and congratulations on a solid quarter. Adam, perhaps I will begin with your comment regarding an anticipated leading position in the U.S. stroke sector within the coming three to four quarters. I suppose, first, a rather fundamental query: ought we to interpret that as meaning you foresee holding a greater than 50% portion of the U.S. stroke market during that same period of three to four quarters? And I suppose, considering the extended schedule for Thunderbolt, does this suggest that SENDit is, by and large, the thing driving you toward that leading position, instead of, more or less, relying on Thunderbolt?

Adam Elsesser

executive
#66

Yeah. Oh, you'd like me to say more about that? So yes, that's correct. SENDit — that's the reason I said we aren't forced to sit around. Once Thunderbolt arrives, there will be additional excitement and greater expansion. Down the road, it will bring us extra gains, but waiting for those gains isn't necessary right now. Back when we initially brought up Thunderbolt, several years back, SENDit didn't exist for us. We had no idea we'd be spared the wait. The reality that no waiting is required — after all of us assumed it was, and suddenly it isn't — works in our favor. Honestly, it's fairly thrilling. So, picture this — at SNIS we had a tech suite set up. Physicians were testing out the products, but without SENDit involved, and what happened was they kept hitting a wall partway along the curve. Then they gave it a shot with SENDit, and they just glided straight up, again and again. People reacted along the lines of, "Wow, that's incredible." And really, this comes down to keeping patients safe. It's about extracting the clot quickly, since — as I said — when Thunderbolt is what you're relying on to pull that clot, even if that step only takes a minute or two, if reaching the site ate up 45 minutes, that scenario still leaves something to be desired. Should you arrive at the location within a couple of minutes and manage to clear the blockage in that same short window, then the job has genuinely been accomplished. At present, our efforts are focused on nailing the initial piece of this scenario — the arrival step, which is, as you know, the crucial one — and afterward we intend to build on it once Thunderbolt arrives. Honestly, that strikes me as a rather solid foundation for achieving favorable outcomes across a great many years.

David Rescott

analyst
#67

Alright, that's useful. I appreciate the more detailed response. My follow-up is about the longer-term objectives for margin — gross margin and operating margin. I believe you mentioned something like gross margins exceeding 70% at some point in the coming years. Could you narrow that down — is it more like a 2 to 3-year horizon, or is it something we'd see within 5 years? And on the operating margin side, given where you are, with the launches and the current sales force, should we expect any acceleration or additional spending on the sales force in the back half of this year and going into 2024? Or are you comfortable with how the business stands right now? Thanks.

Maggie Yuen

executive
#68

Yes, thanks for asking. Regarding gross margin, I believe we've said before that 2 to 3 years out is the appropriate target to focus on. We expect to keep benefiting from all the positive drivers we've observed — mix, volume, scalability, and margin alike.

Adam Elsesser

executive
#69

Regarding the sales force, that’s a good question. We have an amazing group, and we cover the entire U.S. quite well. As territories expand, we might need to bring on one or two people here and there. Mostly, we’re going to be able to gain some real leverage there. We don’t believe we’ll need to. This is kind of the peak busy period for them because they’re rolling out these products, they’re working through the process at all these hospitals, they’re providing case coverage, and as someone mentioned the coil business, I think over time it will become more normalized. Our team is incredible. I highlighted them in the prepared remarks for the sheer amount of work people have put in during the first half of the year. I think we’ll get a lot of leverage from that, because I do not believe we need to fundamentally change the size of the team.

David Rescott

analyst
#70

Thanks.

Jee Hamlyn-Harris

executive
#71

Thanks, operator. Speaking for everyone on our management team, we appreciate all of you once more for being with us today, and for the attention you've shown to Penumbra. We're eager to bring you our latest during the third quarter call.

Operator

operator
#72

Ladies and gentlemen, this concludes today's conference call. You may now-

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.